MedPath

Comparaison du nicotinamide et du sevelamer hydrochloride sur le contrôle de la phosphatémie des hémodialysés chroniques - RENANIC

Conditions
Ostéodystrophie rénale
MedDRA version: 9.1Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disorders
Registration Number
EUCTR2008-004673-17-FR
Lead Sponsor
CHU d'Amiens
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

hommes et femmes âgés de plus de 18 ans,
en dialyse chronique > 3 mois,
PO4 > 1,60 mmol/l,
PCa < 2,37 mmol/l
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

PTH < 60 ou > 800 pg/ml (PTX) ; malade intoxiqué à l’aluminium (aluminémie > 0,5 µmol/l) ; si calcifications aortiques avec un score = 20 (max 24), allergie au Rénagel, au Nicobion, femme enceinte, maladie auto-immune, patient non observant, anomalies des tests hématologiques et hépatiques.
Refus de participer à le recherche

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath